Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene

Mehr zum Buch

The objectives of the review were to evaluate the clinical effectiveness and cost-effectiveness of trastuzumab in the management of advanced breast cancer. Only randomised controlled trials of trastuzumab alone, or in combination with other agents, versus systemic therapy without trastuzumab, were initially considered in the assessment of clinical effectiveness. The assessment of cost effectiveness includes only full economic evaluations. -- abstract.